FY2028 Earnings Forecast for ORKA Issued By Leerink Partnrs

Oruka Therapeutics, Inc. (NASDAQ:ORKA) – Stock analysts at Leerink Partnrs issued their FY2028 earnings per share estimates for shares of Oruka Therapeutics in a research note issued on Wednesday, November 13th. Leerink Partnrs analyst D. Risinger forecasts that the company will earn ($2.92) per share for the year. Leerink Partnrs has a “Strong-Buy” rating on the stock. The consensus estimate for Oruka Therapeutics’ current full-year earnings is ($1.69) per share.

Several other analysts have also recently weighed in on the company. Jefferies Financial Group began coverage on Oruka Therapeutics in a report on Friday, September 13th. They set a “buy” rating and a $40.00 price target for the company. Wedbush started coverage on shares of Oruka Therapeutics in a research report on Wednesday, September 4th. They issued an “outperform” rating and a $40.00 price target for the company. Leerink Partners began coverage on Oruka Therapeutics in a research report on Tuesday, September 17th. They set an “outperform” rating and a $44.00 price target on the stock. Lifesci Capital began coverage on Oruka Therapeutics in a report on Monday, September 16th. They issued an “outperform” rating and a $41.00 price objective for the company. Finally, TD Cowen assumed coverage on Oruka Therapeutics in a report on Monday, September 16th. They set a “buy” rating on the stock. Six analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, Oruka Therapeutics has a consensus rating of “Buy” and a consensus target price of $43.17.

Oruka Therapeutics Stock Up 0.2 %

Shares of ORKA stock opened at $24.04 on Friday. The business’s 50-day moving average is $26.78. The company has a market cap of $29.09 million, a P/E ratio of -3.84 and a beta of 0.87. Oruka Therapeutics has a 52 week low of $18.72 and a 52 week high of $53.88.

Hedge Funds Weigh In On Oruka Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in ORKA. The Manufacturers Life Insurance Company acquired a new stake in shares of Oruka Therapeutics during the third quarter valued at about $1,037,000. Wellington Management Group LLP acquired a new position in Oruka Therapeutics in the 3rd quarter valued at approximately $2,013,000. Janus Henderson Group PLC acquired a new position in Oruka Therapeutics in the 3rd quarter valued at approximately $5,840,000. Redmile Group LLC bought a new position in shares of Oruka Therapeutics during the third quarter valued at $10,091,000. Finally, Frazier Life Sciences Management L.P. acquired a new position in shares of Oruka Therapeutics during the third quarter worth $11,699,000. Institutional investors own 56.44% of the company’s stock.

Oruka Therapeutics Company Profile

ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products.